Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies

Immutep Limited announced the grant of US patent 12,788,796 for combined preparations of eftilagimod alfa (efti) with PD-1 pathway inhibitors for cancer and infection treatment. This is the fifth patent in the family, expiring March 23, 2038, strengthening the company's intellectual property protection for efti-based combination therapies. The patent covers combinations with multiple immunotherapy agents including durvalumab and atezolizumab.